Red Sun Pharmaceutical announced that revenue for the semi-year 2026 was 2.888 billion yuan, down 21.72% year on year; net profit attributable to shareholders of listed companies was 78.0889 million yuan, down 0.69% year on year, and 78.63 million yuan for the first half year of 2025; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 807.15 million yuan, up 16.67% year on year, to 69.1796 million yuan for the first half year of 2025. The company plans not to pay cash dividends, bonus shares, and not to use the Provident Fund to increase share capital.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.